Physician profile
Gary Anthony Abrams
NPI 1770537573
$4,940.72
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $883 · 2022: $31.26 · 2023: $137 · 2024: $2,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,713 · Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,712.50 |
| Food and Beverage | $137.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,712.50 | 2024 | |
| Novartis Pharmaceuticals Corporation | $697.12 | 2020 | |
| Abbvie INC. | $627.55 | 2019-2023 | Creon, Linzess, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.52 | 2019-2020 | |
| Pfizer INC. | $197.24 | 2019-2020 | |
| Janssen Biotech, INC. | $118.09 | 2019 | |
| Qol Medical, LLC | $68.73 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $67.35 | 2019-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $58.55 | 2019-2023 | Entyvio |
| Shionogi INC | $52.96 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.76 | 2023 | Givlaari |
| Gilead Sciences, INC. | $24.76 | 2019 | |
| Ucb, INC. | $24.18 | 2019 | |
| Lucid Diagnostics INC. | $14.67 | 2023 | |
| Genzyme Corporation | $14.17 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $13.88 | 2020 | |
| Allergan, INC. | $13.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Abrams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.